411 related articles for article (PubMed ID: 33382229)
1. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
Huang L; He J
Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
[TBL] [Abstract][Full Text] [Related]
2. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
[TBL] [Abstract][Full Text] [Related]
3. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N
J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388
[TBL] [Abstract][Full Text] [Related]
4. Cancer Immunotherapy: An Overview of Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).
Baglini E; Salerno S; Barresi E; Marzo T; Settimo FD; Taliani S
Mini Rev Med Chem; 2022; 22(14):1816-1827. PubMed ID: 35176979
[TBL] [Abstract][Full Text] [Related]
5. PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway.
Zhou S; Wang B; Wei Y; Dai P; Chen Y; Xiao Y; Xia H; Chen C; Yin W
Cancer Biomark; 2024; 40(1):47-59. PubMed ID: 38306024
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects.
Munari E; Mariotti FR; Quatrini L; Bertoglio P; Tumino N; Vacca P; Eccher A; Ciompi F; Brunelli M; Martignoni G; Bogina G; Moretta L
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066087
[TBL] [Abstract][Full Text] [Related]
7. Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway.
Wang Z; Yuan L; Liao X; Guo X; Chen J
J Med Chem; 2024 Apr; 67(8):6027-6043. PubMed ID: 38598179
[TBL] [Abstract][Full Text] [Related]
8. The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment.
Xu M; Li S
Cancer Lett; 2024 Jul; 593():216969. PubMed ID: 38768681
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.
Wu Q; Jiang L; Li SC; He QJ; Yang B; Cao J
Acta Pharmacol Sin; 2021 Jan; 42(1):1-9. PubMed ID: 32152439
[TBL] [Abstract][Full Text] [Related]
10. Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer.
Ren Y; Song J; Li X; Luo N
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012144
[TBL] [Abstract][Full Text] [Related]
11. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape.
Kirthiga Devi SS; Singh S; Joga R; Patil SY; Meghana Devi V; Chetan Dushantrao S; Dwivedi F; Kumar G; Kumar Jindal D; Singh C; Dhamija I; Grover P; Kumar S
Eur J Pharm Biopharm; 2024 Jul; 200():114323. PubMed ID: 38754524
[TBL] [Abstract][Full Text] [Related]
12. Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy.
Tashireva LA; Muravyova DT; Popova NO; Goldberg VE; Vtorushin SV; Perelmuter VM
Biochemistry (Mosc); 2021 Nov; 86(11):1461-1468. PubMed ID: 34906044
[TBL] [Abstract][Full Text] [Related]
13. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
Chen R; Yuan D; Ma J
Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
[TBL] [Abstract][Full Text] [Related]
14. New advances in the treatment of chondrosarcoma under the PD-1/PD-L1 pathway.
Yin J; Ren P
J Cancer Res Ther; 2024 Apr; 20(2):522-530. PubMed ID: 38687921
[TBL] [Abstract][Full Text] [Related]
15. Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer.
AmeliMojarad M; AmeliMojarad M; Cui X
Pathol Res Pract; 2023 Apr; 244():154338. PubMed ID: 36905697
[TBL] [Abstract][Full Text] [Related]
16. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.
Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
[TBL] [Abstract][Full Text] [Related]
17. PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.
Zhang Y; Yang Y; Chen Y; Lin W; Chen X; Liu J; Huang Y; Wang H; Teng L
Front Immunol; 2022; 13():1060497. PubMed ID: 36505487
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma.
Nanamori H; Sawada Y
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163049
[TBL] [Abstract][Full Text] [Related]
19. PD-1/PD-L1 pathway: Current research in breast cancer.
Syamsu SA; Faruk M; Smaradania N; Sampepajung E; Pranoto AS; Irsandy F; Tammasse IFU
Breast Dis; 2024; 43(1):79-92. PubMed ID: 38701137
[TBL] [Abstract][Full Text] [Related]
20. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.
Yu X; Zhai X; Wu J; Feng Q; Hu C; Zhu L; Zhou Q
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166881. PubMed ID: 37696462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
